尿道感染市场：按治疗、年龄层、性别和最终用户划分－2025-2032 年全球预测

预计到 2032 年，尿道感染市场将成长至 216.6 亿美元，复合年增长率为 7.14%。

主要市场统计数据
基准年2024年	124.7亿美元
预计2025年	133.4亿美元
预测年份：2032年	216.6亿美元
复合年增长率（%）	7.14%

简要概述尿道感染的临床动态变化、患者期望以及影响诊断和治疗途径的相关人员的优先事项

尿道感染(UTI) 是贯穿初级保健、门诊和急诊的临床挑战。临床情势由以下因素决定：不断发展的诊断方法（优先考虑快速症状分类和就地检验）、不断扩展的治疗套件（兼顾疗效和抗菌药物管理）以及患者对可及性和耐受性治疗方案的期望不断提高。这些汇聚的力量正在塑造临床医生、支付方和卫生系统在评估治疗途径和服务模式时如何设定优先事项。

临床医生越来越多地使用将症状评估与针对性检测相结合的整合工作流程，以区分併发症病例和需要升级治疗的病例。同时，药物和非药物治疗方案也越来越受到关注，不仅因为它们可以缓解症状，还因为它们在减少復发和支持抗菌药物管理方面发挥着重要作用。患者和看护者正在寻求能够快速控制症状、副作用最小且易于给药的治疗方法，这些偏好正在影响处方行为和产品开发。

在营运方面，医疗保健提供者正在调整护理路径，以在适当的情况下适应远端医疗、远端监控和居家管理，这凸显了製定完善的临床指南和患者教育的重要性。这些动态共同为从研发到分销再到临床实施的整个价值链的策略决策奠定了基础。

新兴的临床、技术和行为变化从根本上改变了尿道感染治疗格局和相关人员的决策。

尿道感染)领域正在经历一场变革，这得益于诊断技术的进步、对抗生素管理的重新重视以及数位化医疗推动的患者行为的改变。快速分子诊断和照护现场正在减少诊断的不确定性，使临床医生能够更精准地制定治疗方案，并避免不必要的广谱抗生素使用。这种转变强化了临床对标靶药物的偏好，并支持在适当的情况下将非抗生素辅助药物纳入治疗方案。

行为转变同样重要。患者如今期望更快获得治疗，更透明地了解风险和效益，并做出符合其生活方式偏好的选择。远端医疗已发展成为一种可行的初步评估和追踪手段，鼓励将远端系统管理与必要时的现场升级相结合的护理模式。同时，供应链创新，包括製造商和经销商之间更紧密的合作，正在帮助缓解暂时的供不应求，并确保护理的连续性。

技术整合正在重塑临床工作流程。电子健康记录和决策支援系统正在更新，以反映管理原则并促进适当的诊断检测。这些工具有助于更好地监测依从性，并支持真实世界证据的收集，从而为指南的迭代更新提供资讯。这些变革力量的汇聚正在创建一个生态系统，在这个生态系统中，临床有效性、病患体验和营运韧性相互依存。

2025 年美国关税对医药供应链、筹资策略和医疗机构临床可累积影响

2025年美国加征关税将使尿道结石治疗供应链、筹资策略和製造地决策更加复杂。影响原材料、活性药物成分和成品进口的关税可能会改变采购的经济性，促使製造商和经销商重新评估筹资策略，并评估转移生产或寻找其他合格供应商的可行性。因此，医疗系统和支付方可能需要调整其合约方式，以维持医疗服务的可及性和连续性。

除了采购之外，关税还可能影响库存计划週期和商业合约结构。企业可以提高安全库存水准或多元化供应商组合，以降低贸易政策波动带来的风险，因为贸易政策波动会影响营运成本和物流能力。製造商和服务提供者可能会重新考虑近岸外包或在地化策略，以降低关税风险，但此类措施需要前置作业时间、资本投入和监管调整，而这些措施可能会限制回应能力。

临床医生和处方人员应预见产品供应或替代品的潜在变化，这可能需要调整方案并加强患者沟通。付款人和医疗系统可以加强与製造商的合作，设计应急计划，以确保第一线药物的可及性，同时与管理目标保持一致。最终，由价格主导的变化强化了供应链敏捷性、多元化采购和积极主动的相关人员参与的价值，从而在政策驱动的市场波动期间保障病患医疗。

深入细分洞察治疗方式、年龄层、性别和护理环境如何影响临床选择和资源分配

特定细分市场的动态揭示了治疗方式、患者群体和护理点之间存在的微妙机会和摩擦点，直接影响临床决策和商业策略。在治疗类别中，抗生素仍然是急性护理的支柱，磷霉素、呋喃妥因和甲氧芐啶/磺胺甲噁唑等药物根据疗效特征、给药便利性、安全性考虑和管理重点，各自占据着不同的临床领域。同时，D-甘露糖、非那吡啶和益生菌等非抗生素疗法正越来越多地被考虑用于缓解症状、预防復发，或作为循证定制护理计划的辅助手段。

依年龄细分可揭示临床病程和风险考虑的差异。对于成人患者，门诊和远端医疗模式通常有效，且往往提供简单的管理途径；而老年族群则需要关注合併症、多重用药风险以及通常需要多学科协作的非典型病理。儿科护理强调基于体重的给药、看护者教育和儿童友善处方，并受益于清晰的指导，以避免不必要的抗生素暴露。

性别差异会影响盛行率和治疗方法。女性患者中併发症病例的比例较高，而男性患者较可能需要评估潜在的结构性和併发症因素。终端用户细分凸显了诊所和医院在诊断、升级和管理方面的互补作用，随着医疗服务转向门诊管理和患者自我护理，居家照护环境的重要性日益凸显。此类细分洞察有助于制定有针对性的临床指南、处方决策和商业性推广，从而根据特定人群和护理环境的需求客製化产品属性。

针对亚太地区、欧洲、中东和非洲的区域策略考虑，以推动治疗的采用、取得和供应链的弹性

临床实务模式、法律规范和供应链整合的地区差异，导致各主要地区策略重点各异，进而影响尿道结石药物的取得和采用。在美洲，公立和私立支付机构的混合、成熟的分销网络以及较高的门诊利用率，推动了对经济高效、符合指南的治疗方法和弹性物流的需求，以支持以地区为基础的管理。该地区也正在快速普及远端医疗和远端监控，这正在影响治疗方法的处方和实施方式。

在欧洲、中东和非洲地区，法规环境、报销机制和基础设施成熟度差异巨大，需要采取灵活的商业化方法。一些市场透过强有力的抗生素管理计划和集中采购来影响处方决策，而其他市场则专注于改善药物的可及性和诊断能力。因此，製造商和服务供应商需要根据区域政策重点和医疗保健服务模式，调整其参与策略和供应方式。

亚太地区拥有充满活力的製造地，以及快速发展的临床市场。虽然该地区部分地区能够实现大批量生产，支持全球供应，但由于监管途径和处方习惯存在差异，需要调整打入市场策略。在每个地区，与当地经销商伙伴关係、投资诊断能力以及遵循特定地区的临床指南对于确保获得适当的治疗方法和持续的护理至关重要。

竞争格局分析确定了治疗和服务导向相关人员之间的创新途径、伙伴关係模式和商业化策略

专注于治疗创新、诊断整合以及支持管理和以患者为中心的医疗服务交付模式的公司正在塑造尿道结石领域的竞争格局。大型製药公司追求差异化的配方、给药方案和安全性，以满足临床医生和患者的偏好，而规模较小的专科公司则探索新型非抗生素辅助药物和支持性护理药物，以补充传统疗法。对于那些寻求精准治疗决策并透过改善疗效和减少不当抗生素使用来展现价值的公司来说，诊断与治疗的交叉领域是一个不断扩大的策略投资领域。

随着各组织致力于加快产品上市速度、扩大通路并管理供应链风险，製造商、诊断供应商和分销网络之间的伙伴关係与联盟正变得越来越普遍。商业策略强调医生教育、真实世界证据生成以及基于价值的合约模式，将奖励与合理的使用和结果相结合。同时，对生产灵活性和品质保证的投资有助于应对政策变化和突发的供应中断。

服务供应商和临床机构也在不断发展，出现了以门诊病人管理、远端医疗追踪和病患教育为重点的整合照护模式。这些模式为能够提供整合治疗、诊断和数位化支援的捆绑式解决方案的公司创造了机会，能够在依从性、復发预防和患者满意度方面取得显着改善。

为製造商、付款人和医疗保健提供者提供实用、高影响力的策略建议，以提高治疗方法采用率、供应弹性和患者治疗效果

产业领导者应优先考虑一系列策略行动，以提升临床疗效、供应韧性和商业性效益。首先，将产品开发和产品组合定位与管理原则和临床医生工作流程结合，将有助于推广应用。这意味着要强调安全性、易用性以及与管理目标相辅相成的证据。其次，多样化筹资策略并投资于供应链透明度，可以减少贸易政策中断的风险，并确保诊所、医院和居家医疗机构的连续性。

第三，公司和医疗系统应扩大诊断整合力度，以实现更有针对性的治疗选择，并利用即时诊断工具和决策支持，最大限度地减少不必要的抗生素暴露。第四，根据细分市场的实际情况，制定个人化的参与方案，使治疗特征与成人、老年和小儿科的需求一致，并考虑性别特异性的临床模式，这将改善处方调整和患者预后。第五，区域市场策略应在全球一致性与在地化适应性之间取得平衡，并考虑到美洲、欧洲、中东和非洲以及亚太地区不同的监管和报销格局。

最后，製造商、付款人、供应商和经销商之间的积极合作可以製定应对与资费相关的中断的紧急时应对计画，并建立基于价值的安排，以奖励合理使用和可衡量的成果。这些措施合在一起，将增强韧性，提高医疗质量，并使相关人员能够灵活应对临床和政策变化。

透明的调查方法，详细说明用于吸引相关人员、检验数据和产生可靠、可操作的见解的分析框架

本分析采用混合方法调查方法，结合一手资料和二手资料，旨在获得可靠且可操作的见解。主要输入包括与临床医生、药剂师、供应链专家和商业领袖进行结构化访谈，以了解临床实践、采购限制和患者需求的真实观点。此外，我们还对临床指南、监管趋势和技术应用趋势进行了系统性回顾，以补充这些见解，从而为观察到的行为和策略性反应提供背景资讯。

分析方法包括定性主题分析，透过相关人员访谈识别重复出现的模式，以及跨资料流的三角测量来检验结论。情境分析用于探索政策变化和供应链压力源的潜在影响，并强调组织可以部署的营运槓桿。自始至终，我们强调假设的透明度和方法的可复製性，并与独立的临床和供应链专家进行反覆检验，以完善解释并确保其实践相关性。

在原始资料收集过程中，我们遵循了伦理考量和资料隐私通讯协定。本调查方法兼顾了深刻的见解和广阔的视角，为决策者在尿道结石护理生态系统的策略发展和营运规划中提供了坚实的基础。

简要概述关键发现和策略意义，为领导者应对不断变化的尿道感染护理和交付环境提供指导

本文揭示了临床实践、患者期望、供应链动态和当地市场现实等相互关联的力量，这些力量共同影响着尿道感染) 的治疗。有效的尿道感染管理越来越依赖协调诊断准确性、治疗选择和管理原则，以维持治疗效果并优化患者体验。同时，供应链和政策制定需要积极主动的规划，以维持持续的可近性，并在必要时支持实证替代治疗。

决策者应将临床介入和营运介入视为互补。在诊断、临床医生决策支援和患者教育方面的投资可以减少抗生素的不当使​​用并改善治疗效果，而策略性采购和本地市场适应则可以确保药物的可及性和商业性可行性。这种整合凸显了临床负责人、采购团队和相关人员之间跨职能协作的必要性，以便将洞察转化为医疗服务方面可衡量的改进。

随着情况的不断演变，那些整合了以管理为重点的产品策略、弹性供应方式和区域客製化商业化计划的组织将最有能力提供高品质、以患者为中心的尿道结石治疗，同时应对政策和市场的不确定性。持续监测诊断创新、临床证据和贸易政策的趋势，对于维持进展并长期调整策略至关重要。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 临床环境中越来越多地采用快速诊断测试，提高了泌尿道感染管理的准确性和速度
• 为了降低抗生素抗药性，D-甘露糖和益生菌等非抗生素疗法越来越受欢迎。
• 开发针对泌尿道感染病原体的新型窄效抗生素以维持微生物群的完整性
• 在基层医疗环境中越来越多地使用远端医疗平台进行尿道感染的远距离诊断和管理
• 人工智慧演算法整合用于临床决策支援系统中预测尿路感染復发风险分层
• 扩大门诊和社区诊所的抗生素管理项目，以遏制不适当的泌尿道感染处方

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章尿道感染市场（按治疗）

• 抗生素
  • 磷霉素
  • 呋喃妥因
  • 甲氧芐啶/磺胺甲噁唑
• 非抗生素疗法
  • D-甘露糖
  • 非那吡啶
  • 益生菌

第九章尿道感染市场（依年龄层）

• 成人
• 老年人
• 孩子们

第 10 章尿道感染市场：性别

• 女士
• 男性

第 11 章尿道感染市场（依最终用户）

• 诊所
• 居家照护环境
• 医院

第十二章尿道感染市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章尿道感染市场：按组

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章尿道感染市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Astellas Pharma Inc.
  • Bayer AG

The Urinary Tract Infection Market is projected to grow by USD 21.66 billion at a CAGR of 7.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 12.47 billion
Estimated Year [2025]	USD 13.34 billion
Forecast Year [2032]	USD 21.66 billion
CAGR (%)	7.14%

A concise overview of evolving Urinary Tract Infection clinical dynamics, patient expectations, and stakeholder priorities reshaping diagnosis and treatment pathways

Urinary tract infections (UTIs) remain a pervasive clinical challenge that intersects primary care, ambulatory services, and acute care delivery. The clinical landscape is defined by evolving diagnostic approaches that prioritize rapid symptom triage and point-of-care testing, an expanding therapeutic toolkit that balances efficacy with antimicrobial stewardship, and heightened patient expectations for accessible, tolerable treatment options. These converging forces shape how clinicians, payers, and health systems set priorities when evaluating treatment pathways and service models.

Clinicians increasingly rely on integrated workflows that combine symptom assessment with targeted testing to distinguish uncomplicated presentations from cases requiring escalation. Simultaneously, pharmaceutical and non-pharmaceutical options are gaining attention not only for symptomatic relief but also for their roles in reducing recurrence and supporting antimicrobial stewardship. Patients and caregivers are seeking treatments that offer rapid symptom control, minimal adverse effects, and convenient delivery, and these preferences are influencing prescribing behavior as well as product development.

From an operational perspective, healthcare providers are adapting care pathways to accommodate telemedicine encounters, remote monitoring, and home-based management where appropriate, which underscores the need for robust clinical guidelines and patient education. Taken together, these dynamics set the stage for strategic decision-making across the value chain-from research and development to distribution and clinical implementation-requiring stakeholders to align clinical evidence, supply resilience, and patient-centered design.

Emerging clinical, technological, and behavioral shifts that are fundamentally transforming the Urinary Tract Infection care landscape and stakeholder decision-making

The UTI environment is undergoing transformative shifts driven by advances in diagnostics, renewed emphasis on antimicrobial stewardship, and patient behavior changes amplified by digital health adoption. Rapid molecular and point-of-care diagnostics are reducing diagnostic uncertainty, enabling clinicians to tailor therapy more precisely and avoid unnecessary broad-spectrum antibiotic use. This shift is reinforcing a clinical preference for targeted agents and supporting the integration of non-antibiotic adjuncts into care algorithms where appropriate.

Behavioral shifts are equally significant; patients now expect faster care access, greater transparency around risks and benefits, and options that align with lifestyle preferences. Telehealth has matured as a viable modality for initial assessment and follow-up, prompting care models that blend remote management with in-person escalation when indicated. Meanwhile, supply chain innovation, including closer alignment between manufacturers and distributors, is helping to mitigate episodic shortages and ensure treatment continuity across care settings.

Technological integration is beginning to reshape clinical workflows. Electronic health records and decision support systems are being updated to reflect stewardship principles and to prompt appropriate diagnostic testing. These tools facilitate better adherence monitoring and enable real-world evidence collection that informs iterative guideline updates. Collectively, these transformative forces are creating an ecosystem in which clinical effectiveness, patient experience, and operational resilience are increasingly interdependent.

Cumulative consequences of United States tariff measures in 2025 on pharmaceutical supply chains, procurement strategies, and clinical access across care environments

United States tariff actions in 2025 introduce a layer of complexity for supply chains, procurement strategies, and manufacturing footprint decisions that service the UTI treatment continuum. Tariff measures that affect raw materials, active pharmaceutical ingredients, or finished product imports can alter procurement economics, prompting manufacturers and distributors to reassess sourcing strategies and to evaluate the feasibility of shifting production or qualifying additional suppliers. In turn, health systems and payers may need to adjust contracting approaches to maintain access and to preserve therapeutic continuity across care settings.

Beyond procurement, tariffs can influence the cadence of inventory planning and the structure of commercial contracts. Organizations may increase safety stock levels or diversify supplier panels to reduce exposure to trade policy disruption, which has implications for working capital and logistics capacity. Manufacturers and service providers are likely to revisit nearshoring or regionalization strategies to reduce tariff risk, but such moves require lead time, capital investment, and regulatory coordination that can constrain immediate responsiveness.

Clinicians and formulary decision-makers should anticipate potential changes in product availability or substitutions that could require protocol adjustments and enhanced communication with patients. Payers and health systems may intensify collaboration with manufacturers to design contingency plans that preserve access to first-line therapies while aligning with stewardship goals. Ultimately, tariff-driven shifts reinforce the value of supply chain agility, diversified sourcing, and proactive stakeholder engagement to safeguard patient care during policy-induced market fluctuations.

Deep segmentation-driven insights demonstrating how treatment modalities, age cohorts, gender differentials, and care settings shape clinical choices and resource allocation

Segment-specific dynamics reveal nuanced opportunities and friction points across treatment modalities, patient populations, and points of care that directly impact clinical decision-making and commercial strategy. Within treatment categories, antibiotics remain central for acute management, with agents such as fosfomycin, nitrofurantoin, and trimethoprim/sulfamethoxazole each occupying distinct clinical niches based on efficacy profiles, dosing convenience, safety considerations, and stewardship priorities. Concurrently, non-antibiotic therapies such as D-mannose, phenazopyridine, and probiotic interventions are increasingly considered for symptom relief, recurrence prevention, or as adjuncts in tailored care plans where evidence supports their use.

Age-based segmentation highlights differential clinical pathways and risk considerations. Adults tend to present with straightforward management pathways where outpatient and telehealth models are commonly effective, while geriatric populations require heightened attention to comorbidities, polypharmacy risks, and atypical presentations that often necessitate multi-disciplinary coordination. Pediatric care emphasizes weight-based dosing, caregiver education, and child-friendly formulations, and it benefits from clear guidance to avoid unnecessary antibiotic exposure.

Gender-based differences influence both incidence and management approaches, with female patients representing a larger proportion of uncomplicated presentations and male patients more likely to prompt evaluation for underlying structural or complicating factors. End-user segmentation clarifies where value is realized: clinics and hospitals each play complementary roles in diagnosis, escalation, and stewardship, and home care settings are increasingly important as care delivery shifts toward ambulatory management and patient self-care initiatives. These segmentation insights inform targeted clinical guidelines, formulary decisions, and commercial outreach that align product attributes to the needs of specific populations and care settings.

Regional strategic considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific that drive treatment adoption, access, and supply chain resilience

Regional variation in clinical practice patterns, regulatory frameworks, and supply chain integration creates distinct strategic priorities across major geographies that affect access to and adoption of UTI therapies. In the Americas, a mix of public and private payers, established distribution networks, and a high degree of outpatient care utilization emphasize the need for cost-effective, guideline-aligned therapies and resilient logistics to support community-based management. This region also shows rapid uptake of telemedicine and remote monitoring, which influences how treatments are prescribed and delivered.

Within Europe, the Middle East & Africa, heterogeneity is pronounced: regulatory environments, reimbursement mechanisms, and infrastructure maturity differ widely, necessitating flexible commercialization approaches. Some markets have strong antimicrobial stewardship programs and centralized procurement that shape formulary decisions, while others are focused on improving access and diagnostic capacity. Manufacturers and service providers must therefore tailor engagement strategies and supply approaches to account for local policy priorities and healthcare delivery models.

The Asia-Pacific region features dynamic manufacturing hubs alongside markets with rapidly evolving clinical practices. High-volume production capacity in parts of this region supports global supply, but divergent regulatory pathways and localized prescribing habits require adaptive market access strategies. Across all regions, partnerships with local distributors, investments in diagnostic capacity, and responsiveness to region-specific clinical guidelines remain critical to ensuring appropriate therapy utilization and continuity of care.

Competitive landscape analysis revealing innovation pathways, partnership models, and commercialization strategies among therapeutic and service-oriented stakeholders

Competitive dynamics in the UTI space are shaped by companies that focus on therapeutic innovation, diagnostic integration, and service delivery models that support stewardship and patient-centric care. Leading pharmaceutical players pursue differentiated formulations, dosing regimens, and safety profiles to address clinician and patient preferences, while smaller specialty companies explore novel non-antibiotic adjuncts and symptomatic agents that can complement traditional therapy. The intersection of diagnostics and therapeutics is a growing area of strategic investment as companies seek to enable targeted treatment decisions and to demonstrate value through improved outcomes and reduced inappropriate antibiotic use.

Partnerships and alliances between manufacturers, diagnostic providers, and distribution networks are increasingly common as organizations aim to accelerate time-to-market, expand access, and manage supply chain risk. Commercial strategies emphasize physician education, real-world evidence generation, and value-based contracting approaches that align incentives around appropriate use and outcomes. At the same time, investment in manufacturing flexibility and quality assurance helps companies respond to policy shifts and episodic supply disruptions.

Service providers and clinical organizations are also evolving, with integrated care models that prioritize outpatient management, telehealth-enabled follow-up, and patient education. These models create opportunities for companies that can offer bundled solutions-combining therapeutics, diagnostics, and digital support-to demonstrate measurable improvements in adherence, recurrence reduction, and patient satisfaction.

Practical, high-impact strategic recommendations for manufacturers, payers, and providers to enhance therapy adoption, supply resilience, and patient outcomes

Industry leaders should prioritize a set of strategic actions to strengthen clinical outcomes, supply resilience, and commercial effectiveness. First, aligning product development and portfolio positioning with stewardship principles and clinician workflow will support adoption; this means emphasizing safety profiles, dosing simplicity, and evidence that complements stewardship goals. Second, diversifying sourcing strategies and investing in supply chain transparency can reduce exposure to trade policy disruptions and ensure continuity across clinics, hospitals, and home care settings.

Third, companies and health systems should expand diagnostic integration efforts to enable more targeted therapy selection, leveraging point-of-care tools and decision support to minimize unnecessary antibiotic exposure. Fourth, tailored engagement that reflects segmentation realities-matching therapeutic attributes to the needs of adults, geriatrics, and pediatrics, and considering gender-specific clinical patterns-will improve prescribing alignment and patient outcomes. Fifth, regional market strategies should balance global consistency with local adaptation, recognizing the distinct regulatory and reimbursement landscapes across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Finally, proactive collaboration among manufacturers, payers, providers, and distributors can create contingency plans for tariff-related disruptions and establish value-based arrangements that reward appropriate use and measurable outcomes. Executed in concert, these steps enhance resilience, elevate care quality, and position stakeholders to respond nimbly to clinical and policy shifts.

Transparent research methodology detailing stakeholder engagement, data validation, and analytical frameworks used to generate robust and actionable insights

This analysis draws on a mixed-methods research approach combining primary stakeholder engagement, secondary literature synthesis, and cross-functional validation to ensure robust and actionable findings. Primary inputs included structured interviews with clinicians, pharmacists, supply chain professionals, and commercial leaders to capture real-world perspectives on clinical practice, procurement constraints, and patient needs. These insights were complemented by a systematic review of clinical guidelines, regulatory developments, and technology adoption trends to contextualize observed behaviors and strategic responses.

Analytical techniques included qualitative thematic analysis to identify recurring patterns across stakeholder interviews, and triangulation across data streams to validate conclusions. Scenario analysis was used to explore plausible impacts of policy shifts and supply chain stressors, focusing on operational levers that organizations can deploy. Throughout, emphasis was placed on transparency in assumptions and reproducibility of methods, with iterative validation sessions conducted with independent clinical and supply chain experts to refine interpretations and ensure practical relevance.

Ethical considerations and data privacy protocols were observed during primary data collection. The methodology balances depth of insight with breadth of perspective, providing decision-makers with a defensible foundation for strategy development and operational planning within the UTI care ecosystem.

Concise synthesis of critical findings and strategic implications for leaders navigating the evolving Urinary Tract Infection care and supply environment

This synthesis highlights the interconnected nature of clinical practice, patient expectations, supply chain dynamics, and regional market realities that collectively shape UTI care. Effective management of urinary tract infections increasingly depends on aligning diagnostic precision, therapeutic choice, and stewardship principles to preserve treatment efficacy and optimize patient experience. In parallel, supply chain and policy developments require proactive planning to maintain uninterrupted access and to support evidence-based substitution where necessary.

Decision-makers should view clinical and operational interventions as complementary: investments in diagnostics, clinician decision support, and patient education reduce inappropriate antibiotic use and improve outcomes, while strategic sourcing and regional market adaptation preserve access and commercial viability. The convergence of these elements underscores the need for cross-functional collaboration among clinical leaders, procurement teams, and commercial stakeholders to translate insights into measurable improvements in care delivery.

As the landscape continues to evolve, organizations that integrate stewardship-minded product strategies, resilient supply approaches, and regionally attuned commercialization plans will be best positioned to deliver high-quality, patient-centered UTI care while navigating policy and market uncertainties. Continued monitoring of diagnostic innovations, clinical evidence, and trade policy developments will be essential to sustain progress and adapt strategies over time.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of point-of-care rapid diagnostic tests enhancing UTI management accuracy and speed
• 5.2. Growing preference for non-antibiotic therapies such as D-mannose and probiotics to reduce antibiotic resistance
• 5.3. Development of novel narrow-spectrum antibiotics targeting UTI pathogens to preserve microbiome integrity
• 5.4. Increasing utilization of telehealth platforms for remote diagnosis and management of urinary tract infections in primary care settings
• 5.5. Integration of artificial intelligence algorithms for predictive UTI recurrence risk stratification in clinical decision support systems
• 5.6. Expansion of antimicrobial stewardship programs within outpatient and community clinics to curb inappropriate UTI prescriptions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urinary Tract Infection Market, by Treatment

• 8.1. Antibiotics
  • 8.1.1. Fosfomycin
  • 8.1.2. Nitrofurantoin
  • 8.1.3. Trimethoprim/Sulfamethoxazole
• 8.2. Non Antibiotic Therapies
  • 8.2.1. D Mannose
  • 8.2.2. Phenazopyridine
  • 8.2.3. Probiotics

9. Urinary Tract Infection Market, by Age Group

• 9.1. Adults
• 9.2. Geriatrics
• 9.3. Pediatrics

10. Urinary Tract Infection Market, by Gender

• 10.1. Female
• 10.2. Male

11. Urinary Tract Infection Market, by End User

• 11.1. Clinics
• 11.2. Home Care Settings
• 11.3. Hospitals

12. Urinary Tract Infection Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Urinary Tract Infection Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Urinary Tract Infection Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Pfizer Inc.
  • 15.3.2. F. Hoffmann-La Roche Ltd
  • 15.3.3. Johnson & Johnson
  • 15.3.4. Merck & Co., Inc.
  • 15.3.5. GlaxoSmithKline plc
  • 15.3.6. Abbott Laboratories
  • 15.3.7. Thermo Fisher Scientific Inc.
  • 15.3.8. Danaher Corporation
  • 15.3.9. Astellas Pharma Inc.
  • 15.3.10. Bayer AG

LIST OF FIGURES

• FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 117. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 119. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 121. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 123. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 124. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 125. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 126. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 127. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 132. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 133. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 134. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 136. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 137. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 138. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 139. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 140. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 141. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 142. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 146. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 147. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 148. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 151. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 152. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 153. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 154. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 155. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 156. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 179. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 180. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 188. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 189. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 190. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 194. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 195. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 196. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 197. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 199. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 202. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 203. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 204. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 207. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 208. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 209. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 210. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 211. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 212. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 213. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 216. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 217. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 218. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 221. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 222. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 223. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 224. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 225. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 232. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 233. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 234. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 235. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 236. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 237. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 238. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 239. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 240. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 241. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. GCC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GCC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GCC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 246. GCC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 247. GCC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 248. GCC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 249. GCC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 250. GCC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 251. GCC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GCC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GCC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 254. GCC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 255. GCC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. GCC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 260. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 261. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 262. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 263. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 264. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 265. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 266. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 267. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 268. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 269. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. BRICS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. BRICS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. BRICS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 274. BRICS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 275. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 276. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 277. BRICS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 278. BRICS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 279. BRICS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 280. BRICS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 281. BRICS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 282. BRICS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 283. BRICS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. BRICS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 285. G7 URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 286. G7 URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 287. G7 URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 288. G7 URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 289. G7 URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 290. G7 URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 291. G7 URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 292. G7 URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 293. G7 URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 294. G7 URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 295. G7 URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 296. G7 URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 297. G7 URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 298. G7 URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 299. NATO URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 300. NATO URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 301. NATO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 302. NATO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 303. NATO URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 304. NATO URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 305. NATO URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 306. NATO URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 307. NATO URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 308. NATO URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 309. NATO URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 310. NATO URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 311. NATO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 312. NATO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 313. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 314. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 315. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 316. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 317. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 318. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 319. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
• TABLE 320. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
• TABLE 321. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 322. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 323. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
• TABLE 324. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
• TABLE 325. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 326. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 327. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
• TABLE 328. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
• TABLE 329. CANADA URINARY TRACT INFECT